在孕前症的基因治疗:一个新时代的黎明
Fengxuan Sun1, Maureen Peers de Nieuwburgh1,2, Corinne Hubinont3
1Department of Reproduction Physiopathology, Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium.
Hypertension in pregnancy
|May 31, 2024
概括
基因疗法为妊娠前,一种严重的妊娠并发症提供了新的希望. 一种新的siRNA药物向可溶性fms类铁酶-1 (sFLT-1) 在早期临床试验中显示出前景.
科学领域:
- 产科和妇科 产科和妇科
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 遗传学和基因组学 遗传学和基因组学
背景情况:
- 孕前是孕产妇和胎儿死亡的主要原因,由胎盘功能障碍和释放诸如可溶性fms类铁酶-1 (sFLT-1) 等因素驱动.
- sFLT-1通过抑制血管内皮生长因子 (VEGF) 和胎盘生长因子 (PGF) 引起内皮功能障碍.
- 目前治疗孕前的重点是症状管理,分娩是唯一的终极治疗方法.
研究的目的:
- 审查目前的进展和基因疗法的未来前景,以治疗胎盘功能障碍在孕前.
- 突出基因疗法的潜力,作为一种新的治疗策略,用于孕前.
- 讨论与孕前的新兴基因疗法相关的挑战和考虑.
主要方法:
- 对近期关于基因治疗在孕前症中的应用的科学文献的综述.
- 对针对sFLT-1的基于siRNA的疗法作用机制的分析.
- 检查新的孕前治疗方法的临床开发状态,包括CBP-4888.8.
主要成果:
- 基因疗法,特别是针对sFLT-1的siRNA,显示出治疗子宫前的巨大潜力.
- 一种siRNA药物CBP-4888已获得FDA快速跟踪批准,并处于第一阶段临床试验中.
- 基因治疗的进步提供了一个有前途的途径,超出了当前的管理策略.
结论:
- 基因疗法代表了预先怀孕症潜在治疗的重大进步.
- 通过基因疗法针对胎盘功能障碍,例如sFLT-1敲击,具有很大的前景.
- 进一步的研究和临床试验至关重要,以克服挑战,并实现基因治疗预先怀孕症的全部潜力.
相关概念视频
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
432
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
432
01:07Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
01:59CRISPR
50.6K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
50.6K
00:49What is Genetic Engineering?
74.0K
Overview
74.0K
00:59Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K